NASDAQ:CRTX Investor Alert: Investigation Over Potential Wrongdoing at Cortexyme, Inc.

An investigation on behalf of investors in Cortexyme, Inc. (NASDAQ:CRTX) shares over potential wrongdoing at Cortexyme, Inc. was announced.

San Diego, CA — (SBWIRE) — 04/29/2022 — Certain directors of Cortexyme, Inc. are under investigation over potential breaches of fiduciary duties.

Investors who purchased shares of Cortexyme, Inc. (NASDAQ: CRTX) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.

The investigation by a law firm concerns whether certain Cortexyme, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.

San Francisco, CA based Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer’s disease and other degenerative disorders.

On October 26, 2021, Cortexyme, Inc. issued a press release “report[ing] top-line results from its Phase 2/3 GAIN Trial, a double-blind, placebo-controlled study evaluating the efficacy of atuzaginstat (COR388), an investigational orally administered small-molecule that targets gingipain proteases from the bacterium Porphyromonas gingivalis (P. gingivalis).” The press release reported, in relevant part, that the study had failed to meet statistical significance in its co-primary endpoints of improving cognitive and functional abilities in patients with mild-to-moderate Alzheimer’s disease.

Then, on January 26, 2022, Cortexyme disclosed receipt of a letter from the U.S. Food and Drug Administration (“FDA”) advising that the FDA had “plac[ed] a full clinical hold on atuzaginstat’s (COR388) Investigational New Drug application (IND 134303).”

Those who purchased shares of Cortexyme, Inc. (NASDAQ: CRTX) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Christopher Clausen
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

About The Shareholders Foundation
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

For more information on this press release visit: http://www.sbwire.com/press-releases/nasdaqcrtx-investor-alert-investigation-potential-wrongdoing-cortexyme-inc-1356873.htm

Media Relations Contact

Christopher Clausen
Shareholders Foundation
Telephone: 1-858-779-1554
Email: Click to Email Christopher Clausen
Web: https://www.shareholdersfoundation.com/